Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

FijiKava terminates contract with PuMate, appoints RooLife to market products in China and Australia

  • In News
  • April 12, 2023
  • Alinda Gupta
FijiKava terminates contract with PuMate, appoints RooLife to market products in China and Australia

The global health and wellness market, valued at $7.07 billion in 2021, is projected to exceed $19 billion by 2031. Following the pandemic, people are reevaluating their approach to health, leading to a surge in demand for health and wellness products. FijiKava (ASX: FIJ), a producer of natural, medicinally-based products such as dietary shots, drinking kava, sleep aid capsules, and drinks, is capitalising on this trend and pushing hard into China. 

To expand its presence, FijiKava has entered into an exclusive distribution agreement with China-centric eCommerce distributor RooLife Group (ASX: RLG). In addition to selling FijiKava’s products, RooLife will also provide digital marketing, social media, and other operational support in China and Australia. RooLife will collaborate with FijiKava to co-market the FijiKava powdered drinking kava range alongside RLG’s VORA protein range in the booming online sports nutrition market in China, where over 80% of sales are conducted online.

FijiKava Limited CEO, Anthony Noble, shared, “Alongside the USA, the Chinese market is the biggest international opportunity for FijiKava’s products. This agreement represents work that has been ongoing for more than a year between RooLife and FijiKava, and I am excited to see this come to life in the months ahead.”

As a result of this new agreement, FijiKava Limited has terminated its distribution contract with PuMate Shanghai.

RooLife Group CEO, Bryan Carr, commented, “We are delighted to be working with FijiKava and with the opportunity to market and sell their natural and healthy functional beverages, drinking powders, dietary shots and capsules. It is a natural alignment with our health and wellbeing positioning and digital marketing and e-commerce capabilities in the two key markets for both companies of Australia and China and fits perfectly with our VORA health product range. We look forward to a long and mutually successful partnership.”

As per the agreement, RooLife will be paid for providing digital marketing, social media and eCommerce store operations and receive a margin on all products it sells. The Company has been granted performance rights to achieve retail sales of up to $15 million, with a minimum of $9 million in China, over five years. The initial term of the agreement is two years with periodic reviews of marketing spend, which is funded by FijiKava and may be increased or ceased.

RooLife will also manage and operate FijiKava’s Australian-based online sales operations via the FijiKava website.

Noble added, “RooLife has a proven track record in China with Remedy Kombucha, so we are confident that they can grow an Australian brand through Chinese eCommerce channels and then transition to bricks and mortar retail in the world’s largest consumer market.”

As part of the exclusive agreement, RooLife may receive FIJ shares if it achieves certain sales milestones, including reaching specific levels of retail sales and sales to China by certain deadlines. Given that RooLife dubs itself as a “brand activation agency”, the new venture should be nothing short of a cakewalk.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx fij
  • Bryan Carr
  • fijikava
  • pumate
  • RLG
  • roolife
  • RooLife Group
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.